Physician profile
Daniel Behroozan
NPI 1851325716
$138,797.58
in general payments reported to CMS, 2019-2025
43 companies · $9,857 in 2025
The $9,857 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $27K · 2021: $13K · 2022: $23K · 2023: $41K · 2024: $11K · 2025: $9,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $9,099 · Travel and Lodging: $2,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,356.42 |
| Food and Beverage | $9,099.37 |
| Travel and Lodging | $2,672.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $95,930.84 | 2019-2025 | Aklief, Oracea, Epsolay |
| Pfizer INC. | $23,269.66 | 2019-2023 | |
| Abbvie INC. | $5,145.61 | 2023-2025 | Botox |
| Allergan, INC. | $4,659.07 | 2019-2023 | |
| Biofrontera INC. | $1,547.59 | 2020-2022 | |
| Amgen INC. | $1,491.55 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $755.09 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $749.09 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $608.58 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $562.78 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Journey Medical Corporation | $524.08 | 2020-2025 | |
| Leo Pharma INC. | $420.06 | 2019-2025 | Anzupgo, Adbry |
| Almirall LLC | $386.44 | 2019-2025 | Klisyri, Seysara |
| Sun Pharmaceutical Industries INC. | $328.00 | 2020-2025 | Winlevi |
| Epi Health, LLC | $261.22 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Behroozan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.